Last updated on May 2020

A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)


Brief description of study

This study is designed to evaluate how the body processes and removes mirikizumab. The study will also evaluate safety and disease response in pediatric participants with UC taking mirikizumab. The study will last about 52 weeks and may include up to 17 visits.

Clinical Study Identifier: NCT04004611

Find a site near you

Start Over